40662-14-4

Basic information

• Product Name: 2H-1-Benzopyran-2-one, 3,4-dihydro-4,4,5,7-tetramethyl-
• CAS NO: 40662-14-4
• Molecular Formula: C13H16O2
• Molecular Weight: 204.269
• Mol File: 40662-14-4.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 296.6±40.0 °C(Predicted)
• Density: 1.048±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2H-1-Benzopyran-2-one, 3,4-dihydro-4,4,5,7-tetramethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-1-Benzopyran-2-one, 3,4-dihydro-4,4,5,7-tetramethyl-(40662-14-4)
• EPA Substance Registry System: 2H-1-Benzopyran-2-one, 3,4-dihydro-4,4,5,7-tetramethyl-(40662-14-4)

Safety Data

• Hazardous Substances Data: 40662-14-4(Hazardous Substances Data)

Upstream product

• 638-10-8 ethyl 3-methylbut-2-enoate 
• 108-68-9 3,5-Dimethylphenol 
• 1096058-76-2 C₄₀H₄₁N₃O₇ 
• 129967-43-7 3-(2'-(Benzyloxy)-4',6'-dimethylphenyl)-3,3-dimethylpropanol 
• 129967-44-8 3-(2'-(Benzyloxy)-4',6'-dimethylphenyl)-3,3-dimethylpropionaldehyde 
• 183867-91-6 Phosphoric acid mono-{2-[2-(4-methoxy-phenylcarbamoyl)-1,1-dimethyl-ethyl]-3,5-dimethyl-phenyl} ester 
• 924-50-5 Methyl 3,3-dimethylacrylate 
• 129967-47-1 4-Methoxyaniline 3-(2'-Hydroxy-4',6'-dimethylphenyl)-3,3-dimethylpropionic Acid Amide 
• 40662-08-6 3-(2-Hydroxy-4,6-dimethyl-phenyl)-3-methyl-butyric acid 
• 541-47-9 3-Methylbutenoic acid 
• 129967-46-0 4-Methoxyaniline 3-(2'-(Benzyloxy)-4',6'-dimethylphenyl)-3,3-dimethylpropionic Acid Amide 
• 129967-45-9 3-(2'-(Benzyloxy)-4',6'-dimethylphenyl)-3,3-dimethylpropionic Acid 
• 129967-42-6 2‐(3‐hydroxy‐1,1‐dimethylpropyl)‐3,5‐dimethylphenol 

Relevant articles and documents

Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation

Purpose. To evaluate the cellular permeation characteristics and the chemical and enzymatic stability of phenylpropionic acid-based cyclic prodrugs 1 and 2 of opioid peptides [Leu5]-enkephalin (H-Tyr-Gly-Gly-Phe- Leu-OH) and DADLE (H-Tyr-D-Ala-Gly-Phe-D-Leu-OH), respectively. Methods. The rates of conversion of cyclic prodrugs 1 and 2 to [Leu5]-enkephalin and DADLE, respectively, in HBSS, pH 7.4 (Caco-2 cell transport buffer) and in various biological media having measurable esterase activity were determined by HPLC. The cell permeation characteristics of [Leu5]-enkephalin, DADLE, and cyclic prodrugs 1 and 2 were measured using Caco-2 cell monolayers grown onto microporus membranes and monitored by HPLC. Results. In HBSS, pH 7.4, cyclic prodrugs 1 and 2 degraded to [Leu5]-enkephalin and DADLE, respectively, in stoichiometric amounts. In 90% human plasma, the rates of disappearance of cyclic prodrugs 1 and 2 were slightly faster than in HBSS, pH 7.4. These accelerated rates of disappearance in 90% human plasma could be reduced to the rates observed in HBSS, pH 7.4, by pretreatment of the plasma with paraoxon, a known inhibitor of serine-dependent esterases. In homogenates of Caco-2 cells and rat liver, accelerated rates of disappearance of cyclic prodrugs 1 and 2 were not observed. When applied to the AP side of a Caco-2 cell monolayer, cyclic prodrug 1 exhibited significantly greater stability against peptidase metabolism than did [Leu5]-enkephalin. Cyclic prodrug 2 find DADLE exhibited stability similar to prodrug 1 when applied to the AP side of the Caco-2 cell monolayers. Prodrug 1 was 1680 fold more able to permeate the Caco-2 cell monolayers than was [Leu5]-enkephalin, in part because of its increased enzymatic stability. Prodrug 2 was shown to be approximately 77 fold more able to permeate a Caco-2 cell monolayer than was DADLE. Conclusions. Cyclic prodrugs 1 and 2, prepared with the phenylpropionic acid promoiety, were substantially more able to permeate Caco-2 cell monolayers than were the corresponding opioid peptides. Prodrug 1 exhibited increased stability to peptidase metabolism compared to [Leu5]- enkephalin. In 90% human plasma but not in Caco-2 cell and rat liver homogenates, the opioid peptides were released from the cyclic prodrugs by an esterase-catalyzed reaction that is sensitive to paraoxon inhibition. However, the rate of this bioconversion appears to be extremely slow.

Esterase-Sensitive Glutathione Persulfide Donor

An esterase-sensitive glutathione persulfide (GSSH) donor (BW-GP-401) is described. The release profile was studied by monitoring the formation of lactone and direct trapping of GSSH with 1-fluoro-2,4-dinitrobenzene (DNFB). The donor was examined for its

COMPOUNDS USEFUL IN HIV THERAPY

The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.

NRTI THERAPIES

Polymer-of-prodrug (POP) materials enable new nucleoside reverse transcriptase inhibitor (NRTI) therapy strategies. The materials are prodrugs of NRTIs in the form of polymers. Suitable materials include products which are polymeric NRTI delivery systems comprising polymeric materials which are capable of degradation after administration to release NRTIs or NRTI prodrugs which themselves are capable of metabolism to the parent NRTIs. The NRTIs may optionally be selected from tenofovir (TFV), emtricitabine (FTC), lamivudine (3TC) and MK-8591 (EFdA). The invention facilitates long-acting (LA) regimens. Constructs of the materials may be in the form of injectable compositions or implants.